Загрузка...
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease
Despite the advent of biological products, such as anti-tumor necrosis factor-α monoclonal antibodies (infliximab and adalimumab), for treatment of moderate to severe cases of inflammatory bowel disease (IBD), most patients depend upon aminosalicylates as the conventional treatment option. In recent...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Baishideng Publishing Group Co., Limited
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3974523/ https://ncbi.nlm.nih.gov/pubmed/24707139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i13.3564 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|